Pharmamarketeer

Abbott’s COAPT trial data shows MitraClip device is cost effective, increases life expectancy and improves quality of life

Abbott announced new analyses of the landmark COAPT Trial that show the company’s MitraClip device is cost effective and is projected to increase both life─expectancy and quality of life compared to guideline─directed medical therapy

Medhc-fases-banner
Advertentie(s)